Condition: Primary IgA Nephropathy · Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN). The study consists of a screening period, a run-in period, a 48-week double-blind treatment period, and a 12-week follow-up period. Approximately 84 IgAN patients will be included.
This description comes directly from the study's public registry record.
Kunming Li · 0518-82342973 · kunming.li@hengrui.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07354932